Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 1, 2006, Pages 17-25

  Dansirikul, C ^a,b   Staatz, C E ^a   Duffull, S B ^a   Taylor, P J ^a   Lynch, S V ^a   Tett, S E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b SILPAKORN UNIVERSITY   (Thailand)

Author keywords

Adverse outcomes; Liver transplant; Pharmacodynamics; Tacrolimus

Indexed keywords

TSUKUBAENOLIDE;

ADULT; AKINETIC MUTISM; AREA UNDER THE CURVE; ARTICLE; ATAXIC APHASIA; BRAIN DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMA; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEADACHE; HUMAN; HYPERESTHESIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; INFECTION; INSOMNIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; NEPHROTOXICITY; NEUROTOXICITY; PHOTOPHOBIA; PREDICTION; PSYCHOSIS; SEIZURE; TREATMENT OUTCOME; TREMOR;

ADULT; AREA UNDER CURVE; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LIVER TRANSPLANTATION; MALE; MODELS, THEORETICAL; TACROLIMUS;

EID: 33645118544     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00697.x     Document Type: Article

References (32)

1. Kahan BD Keown P Levy GA Johnston A 2002 Therapeutic drug monitoring of immunosuppressant drugs in clinical practice Clinical Therapeutics 24 330 350
2. Kasiske BL Heim-Duthoy K Rao KV Awni WM 1988 The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients Transplantation 46 716 722
3. Lindholm A Kahan BD 1993 Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation Clinical Pharmacology & Therapeutics 54 205 218
4. Mahalati K Belitsky P Sketris I et al. 1999 Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation Transplantation 68 55 62
5. Undre NA van Hooff J Christiaans M et al. 1999 Low systemic exposure to tacrolimus correlates with acute rejection Transplantation Proceedings 31 296 298
6. Levy G Burra P Cavallari A et al. 2002 Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-h post-dose levels (C2) Transplantation 73 953 959
7. Canadian Neoral Renal Transplantation Study Group 2001 Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation Transplantation 72 1024 1032
8. Mekki Q Lee C Aweeka F et al. 1993 Pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients (abstract PIII-130) Clinical Pharmacology & Therapeutics 53 238
9. Ringe B Braun F Schutz E et al. 2001 A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil Transplantation 71 508 515
10. Venkataramanan R Shaw LM Sarkozi L et al. 2001 Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients Journal of Clinical Pharmacology 41 542 551
11. Winkler M Ringe B Baumann J et al. 1994 Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression Clinical Chemistry 40 2247 2253
12. Backman L Nicar M Levy M et al. 1994 FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects Transplantation 57 519 525
13. Kershner RP Fitzsimmons WE 1996 Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation Transplantation 62 920 926
14. Japanese FK 506 Study Group 1991 Japanese study of FK 506 on kidney transplantation: results of an early phase II study Transplantation Proceedings 23 3071 3074
15. Laskow DA Vincenti F Neylan JF et al. 1996 An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group Transplantation 62 900 905
16. Bottiger Y Brattstrom C Tyden G et al. 1999 Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients British Journal of Clinical Pharmacology 48 445 448
17. Jain A Reyes J Kashyap R et al. 2000 Long-term survival after liver transplantation in 4,000 consecutive patients at a single center Annals of Surgery 232 490 500
18. Jain AB Kashyap R Rakela J et al. 1999 Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events Liver Transplantation and Surgery 5 144 150
19. Wiesner RH 1998 A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group Transplantation 66 493 499
20. Sonoda T Takahara S Takahashi K et al. 2003 Outcome of 3 years of immunosuppression with tacrolimus in more than 1,000 renal transplant recipients in Japan Transplantation 75 199 204
21. Undre N Moller A 1994 Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group Transplantation International 7 S15 S21
22. Cantarovich M Fridell J Barkun J et al. 1998 Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus Transplantation Proceedings 30 1460 1461
23. Ku YM Min DI 1998 An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants Therapeutic Drug Monitoring 20 219 223
24. Wong KM Shek CC Chau KF Li CS 2000 Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients American Journal of Kidney Disease 35 660 666
25. Pisitkun T Eiam-Ong S Chusil S et al. 2002 The roles of C(4) and AUC(0-4) in monitoring of tacrolimus in stable kidney transplant patients Transplantation Proceedings 34 3173 3175
26. Dansirikul C Staatz CE Duffull SB et al. 2004 Sampling times for monitoring tacrolimus in stable adult liver transplant recipients Therapeutic Drug Monitoring 26 593 599
27. Taylor PJ Jones A Balderson GA et al. 1996 Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry Clinical Chemistry 42 279 285
28. Cockcroft DW Gault MH 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41
29. Boeckmann AJ Sheiner BL Beal SL eds 1994 NONMEM users guide-part V: introductory guide San Francisco NONMEM Project Group, University of California at San Francisco
30. O'Grady JG Burroughs A Hardy P et al. 2002 Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial Lancet 360 1119 1125
31. Margarit C Rimola A Gonzalez-Pinto I et al. 1998 Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation Transplantation International 11 Suppl. 1 S260 S266
32. Mor E Patel T Glabman S et al. 1994 Comparison of short and long-term renal function in liver transplant patients receiving cyclosporin or FK 506 Transplantation International 7 Suppl. 1 S77 S80